Analytical Data
-
基因名
MYLC2PL
- Application
-
别名
MYL10; MYLC2PL; PLRLC; Myosin regulatory light chain 10; Myosin light chain 2; lymphocyte-specific; Precursor lymphocyte-specific regulatory light chain
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9BUA6
-
表达区间
1-226 aa
-
氨基酸序列
MLLRLVSNSW PQVILPPRPP KVLGLQAPRR ARKRAEGTAS SNVFSMFDQS QIQEFKESLA LSPRLERNGM ISAHCNLCLT GSSNSPASAS QAFTIMDQNR DGFIDKEDLR DTFAALGRIN VKNEELEAMV KEAPGPINFT VFLTMFGEKL KGTDPEETIL HAFKVFDTEG KGFVKADVIK EKLMTQADRF SEEEVKQMFA AFPPDVCGNL DYRNLCYVIT HGEEKD
-
分子量
25.3 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MYLC2PL is a recombinant protein derived from the MYLC2 gene, which encodes the regulatory light chain of myosin in cardiac muscle. The significance of MYLC2PL research lies in its potential implications for understanding cardiac muscle function and the molecular mechanisms underlying heart diseases. Abnormalities in myosin light chain phosphorylation can lead to various cardiac dysfunctions, including hypertrophic cardiomyopathy and heart failure. By studying MYLC2PL, researchers aim to elucidate the protein's role in muscle contraction, cellular signaling, and its interactions with other contractile proteins. Additionally, the exploration of MYLC2PL can contribute to the development of therapeutic strategies targeting cardiac conditions, providing insights into gene therapies and protein-engineering approaches. Advances in methods such as CRISPR and recombinant DNA technology have facilitated the production and analysis of MYLC2PL, enabling scientists to investigate its structure-function relationships and post-translational modifications in detail. Overall, the study of MYLC2PL is vital for expanding our understanding of cardiac physiology and pathology, potentially leading to innovative treatments for heart disease.
